Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) Director Nancy J. Hutson unloaded 9,000 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $65.00, for a total value of $585,000.00. Following the completion of the transaction, the director now directly owns 5,951 shares in the company, valued at approximately $386,815. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 1.85% on Monday, hitting $64.56. The stock had a trading volume of 646,394 shares. Cubist Pharmaceuticals has a 52-week low of $58.50 and a 52-week high of $82.12. The stock’s 50-day moving average is $64.68 and its 200-day moving average is $69.53. The company has a market cap of $4.889 billion and a P/E ratio of 556.05.

Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Tuesday, July 22nd. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.71 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $58.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $79.64.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.